Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
MHRA Licenses Brensocatib for Non-Cystic Fibrosis Bronchiectasis
The MHRA has granted a marketing authorisation for brensocatib (Brinsupri), the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older. This marks a significant advancement in treatment options for NCFB patients in the UK.
MHRA Class 2 Medicines Recall: KidNaps Melatonin Oral Solution
The MHRA has issued a Class 2 medicines recall for all batches of KidNaps Melatonin 1mg in 1ml Oral Solution due to out-of-specification stability results. Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are conducting the recall at the wholesaler and pharmacy level.
MHRA Statement on PATHWAYS Puberty Blocker Trial Safety
The MHRA has issued a statement regarding the PATHWAYS puberty blocker trial, expressing concerns about participant wellbeing and initiating scientific dialogue with the trial sponsor, King's College London. The agency is applying high scrutiny to ensure the safety of potential child and young person participants.
MHRA Approves Zanidatamab for HER2+ Biliary Tract Cancer
The MHRA has approved zanidatamab (Ziihera) for adult patients with HER2-positive biliary tract cancer that has progressed after previous treatment. This approval provides a new treatment option for a specific patient population with an unmet clinical need.
MHRA: UK Medical Device Testing Hits Record High, Backs AI
The UK's MHRA reported a 17% increase in approved medical device clinical investigations in 2025. The agency is implementing measures to support innovation, including a fee waiver pilot for small firms and enhanced support for AI and neurotechnology.
MHRA Medical Device Safety Notices
The MHRA has issued a list of eight medical device safety notices published between February 9-13, 2026. These notices cover various devices including ventilator circuits, tissue reconstructive material, and PET/CT scanners. The MHRA publishes these for informational purposes.
MHRA Consultation on Indefinite Recognition of CE-Marked Medical Devices
The MHRA has launched a consultation on proposals for the indefinite recognition of CE-marked medical devices in Great Britain. The consultation seeks feedback on extending current transitional arrangements and introducing an international reliance route to ensure continued supply and patient access to medical technologies. The deadline for feedback is April 10, 2026.
MHRA Consultation on CE Marked Medical Device Recognition
The MHRA has launched a consultation on proposals for the indefinite recognition of CE-marked medical devices in Great Britain. The consultation seeks views on extending transitional arrangements for MDD-compliant devices and indefinitely recognising EU MDR/IVDR compliant devices, with a comment deadline of April 10.
MHRA Seizes 20 Million Illegal ED Pills, Warns Against Online Buys
The MHRA announced the seizure of nearly 20 million illegal erectile dysfunction pills between 2021 and 2025, including 4.4 million in 2025 alone. The agency is warning the public against purchasing unauthorized medicines online due to significant health risks.
Missouri Failed to Collect $12.2M in Medicaid Drug Rebates
The HHS Office of Inspector General (OIG) found that Missouri failed to collect $12.2 million in federal rebates for Medicaid physician-administered and pharmacy drugs between January 1, 2019, and December 31, 2022. The OIG recommends Missouri refund the federal government $9.7 million for physician-administered drugs and $2.5 million for pharmacy drugs.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
620 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.